| 2019 | 2018 | 2017 | 2016 | 2015 |
Ocular Therapeutix, Inc. (Nasdaq: OCUL) to Ring The Nasdaq Stock Market Opening Bell
December 14, 2015
Ocular Therapeutix™ Announces Encouraging Top-Line Results from Exploratory Phase 2 Trial for DEXTENZA™ in Patients with Inflammatory Dry Eye Disease
December 14, 2015
Ocular Therapeutix™ Announces FDA Acceptance of NDA Filing for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain
December 09, 2015
Ocular Therapeutix™ Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
November 24, 2015
Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference
November 24, 2015
Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results
November 10, 2015
Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O’Shea
November 09, 2015
Ocular Therapeutix™ to Report Third Quarter 2015 Financial Results
November 03, 2015
Ocular Therapeutix™ to Participate in Three Conferences in November 2015
October 28, 2015
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
October 22, 2015
Ocular TherapeutixTM Reports on Topline Results of Phase 2b Glaucoma Clinical Trial
October 22, 2015
Ocular Therapeutix™ Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Post-Surgical Ocular Inflammation and Pain
October 14, 2015
Ocular Therapeutix™ Submits New Drug Application to U.S. Food and Drug Administration for DEXTENZA® for the Treatment of Post-Surgical Ocular Pain
September 28, 2015
Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.
September 14, 2015
Ocular Therapeutix™ to Participate in Two Investor Conferences in September 2015
September 03, 2015
Ocular Therapeutix™ Reports Second Quarter 2015 Financial Results
August 10, 2015
Ocular Therapeutix™ to Report Second Quarter 2015 Financial Results
August 03, 2015
Ocular Therapeutix™ to Participate at the Cantor Fitzgerald Inaugural Healthcare Conference
June 30, 2015
Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
June 16, 2015
Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock
June 04, 2015
Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock
June 02, 2015
Ocular Therapeutix™ Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results
May 15, 2015
Ocular Therapeutix™ to Report First Quarter 2015 Financial Results
May 06, 2015
Ocular Therapeutix to Present Eight Posters Highlighting its Sustained Release Hydrogel Platform Technology at the Association for Research in Vision and Ophthalmology Annual Meeting
May 01, 2015
Ocular Therapeutix™ Reports Topline Clinical Data for its Second Phase 3 Clinical Trial Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain
April 06, 2015
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2014 Financial Results
March 10, 2015
Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain
March 10, 2015
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2014 Financial Results
March 03, 2015
Ocular Therapeutix™ to Participate in Two Upcoming Investor Conferences
February 19, 2015
Ocular Therapeutix™ to Present at the 17th Annual BIO CEO & Investor Conference
February 04, 2015
Ocular Therapeutix™ Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone for the Treatment of Dry Eye Disease
January 21, 2015
